Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Interest in Shares

13 Mar 2008 12:26

Oxford Biomedica PLC13 March 2008 For Immediate Release 13 March 2008 Oxford BioMedica plc ("the Company") Directors' Interest in Shares and Share Options Oxford BioMedica (OXB:L) The Company today announced that on 13 March 2008 thefollowing awards under the Oxford BioMedica plc Long Term Incentive Plan (LTIP)were made to six executive directors. LTIP: Total shares Percentage of number of over which issued shares shares options are under option awarded held (note 1) Alan Kingsman 1,291,871 2,605,404 0.49%Susan Kingsman 565,640 1,643,331 0.31%Michael McDonald 1,017,542 3,087,843 0.57%Andrew Wood 977,533 2,384,974 0.44%Peter Nolan 771,400 1,612,355 0.30%Nick Woolf 788,582 2,434,867 0.45% Note 1: The total shares over which options are held (share options grantedbetween April 2001 and September 2006 and LTIPs awarded since March 2007)following the awards described above. The share price on which the awards were calculated was 22.5p (the closing priceon the day preceding the awards). The LTIP awards are nil-cost options. The LTIPawards are subject to a three year holding period, and are exercisable on thethird anniversary of the award, subject to the satisfaction of a TotalShareholder Return (TSR) performance condition described below. No awards will be released at the testing date for less than median performanceof Oxford BioMedica TSR compared to a comparator group made up of 20 companiesfrom the biotechnology and healthcare sectors. Median performance will result inrelease of 25% of the shares. Upper quartile performance (i.e. greater than 75thpercentile performance) will result in release of 100% of the shares, withstraight line release between these points. If the performance conditions arenot satisfied or partially satisfied at the end of the holding period, the LTIPaward or the balance of the award (as appropriate) not released shall lapse.There will be no re-testing of the performance conditions. Andrew Wood Company Secretary, Oxford BioMedica plc 13 March 2008 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSTotal Voting Rights
22nd Aug 20237:00 amRNSExpanded agreement with Cabaletta Bio
14th Aug 20237:00 amRNSNotice of Interim Results
1st Aug 20237:00 amRNSTotal Voting Rights
3rd Jul 20234:31 pmRNSPDMR Dealings
3rd Jul 20237:00 amRNSOxford Biomedica PLC - Block Listing Return
3rd Jul 20237:00 amRNSTotal Voting Rights
23rd Jun 20235:32 pmRNSResult of AGM
6th Jun 20233:59 pmRNSTotal Voting Rights
15th May 20237:00 amRNSOxford Biomedica launches TetraVecta system
10th May 20237:00 amRNSBlock listing Application
5th May 20237:00 amRNS2023 AGM Notification
2nd May 20237:00 amRNSTotal Voting Rights
28th Apr 20237:59 amRNS2022 Annual Report and Accounts
26th Apr 20237:00 amRNSBoard Appointment
25th Apr 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
19th Apr 20236:26 pmRNS2022 Preliminary results revised date
3rd Apr 20231:19 pmRNSTotal Voting Rights
30th Mar 20237:00 amRNSNotice of Preliminary Results
13th Mar 202311:33 amRNSOXB confirms no exposure to SVB receivership
1st Mar 202311:16 amRNSTotal Voting Rights
20th Feb 20237:00 amRNSDr Frank Mathias to join as new CEO on 27 March
1st Feb 202310:18 amRNSTotal Voting Rights
27th Jan 20237:00 amRNSBoard Change
3rd Jan 20235:19 pmRNSBlock listing return
3rd Jan 202311:28 amRNSTotal Voting Rights
21st Dec 202212:00 pmRNSOxford Biomedica to Present at J.P Morgan
14th Dec 20227:00 amRNSOxford Biomedica Solutions forms new partnerships
22nd Nov 20227:00 amRNSOxford Biomedica Appoints Frank Mathias as CEO
15th Nov 20222:35 pmRNSHolding(s) in Company
14th Nov 20227:00 amRNSSale and leaseback of Windrush Court facility
1st Nov 20229:14 amRNSTotal Voting Rights
14th Oct 20222:28 pmRNSPDMR Dealings
12th Oct 20227:00 amRNSPDMR Dealings
12th Oct 20227:00 amRNSPDMR Dealings
7th Oct 20221:16 pmRNSPDMR Dealing Amendment
7th Oct 202212:28 pmRNSPDMR Dealing
7th Oct 20227:00 amRNSAmendment of Short-Term Loan Facility
3rd Oct 20229:34 amRNSTotal Voting Rights
15th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOxford Biomedica Solutions signs new partner
7th Sep 20227:00 amRNSLicence & Supply Agreement with New Partner
1st Sep 20229:51 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSNotice of Interim Results
16th Aug 20227:00 amRNSOxford Biomedica Notes Homology Q2 Report
1st Aug 20229:42 amRNSTotal Voting Rights
27th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
26th Jul 20227:00 amRNSLicence & Supply Agreement with New Partner
26th Jul 20227:00 amRNSNew Project with Orchard Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.